Fulcrum Therapeutics (FULC) Enterprise Value (2019 - 2025)
Fulcrum Therapeutics (FULC) has disclosed Enterprise Value for 7 consecutive years, with -$352.3 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 46.17% to -$352.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$352.3 million, a 46.17% decrease, with the full-year FY2025 number at -$352.3 million, down 46.17% from a year prior.
- Enterprise Value was -$352.3 million for Q4 2025 at Fulcrum Therapeutics, down from -$47.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$25.6 million in Q4 2023 to a low of -$352.3 million in Q4 2025.
- A 5-year average of -$86.8 million and a median of -$47.1 million in 2025 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 66.93% in 2022, then crashed 842.85% in 2024.
- Fulcrum Therapeutics' Enterprise Value stood at -$35.4 million in 2021, then grew by 0.89% to -$35.1 million in 2022, then grew by 27.17% to -$25.6 million in 2023, then plummeted by 842.85% to -$241.0 million in 2024, then plummeted by 46.17% to -$352.3 million in 2025.
- Per Business Quant, the three most recent readings for FULC's Enterprise Value are -$352.3 million (Q4 2025), -$47.1 million (Q3 2025), and -$226.6 million (Q1 2025).